IL6 and acute respiratory distress syndrome: This augmented risk is motivated by the SARS-CoV-2 infection itself, the prolonged ICU stay, exposure to broad-spectrum antibiotics, the development of acute respiratory distress syndrome, or the use of immunosuppressive therapies such as corticosteroids or interleukin-6 inhibitors including tocilizumab [21,22,23,24,25].